CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
study drug, Nivolumab as a possible treatment for triple-negative breast cancer that has spread to other parts of the body.The inte...
Phase 2
Stamford, Connecticut, United States and 9 other locations
This research study involves pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA and PAL...
Phase 2
New Haven, Connecticut, United States and 8 other locations
participants with early-stage high-risk hormone receptor positive breast cancer.The names of the study drugs involved in this study...
Phase 2
Stamford, Connecticut, United States and 11 other locations
This research study is evaluating how well Breast Cancer responds to preoperative treatment with Endocrine treatment in combination ...
Phase 2
Stamford, Connecticut, United States and 10 other locations
This research study is for patients with metastatic breast cancer.* Metastatic means that the cancer has spread beyond the ...
Phase 2
Commack, New York, United States and 19 other locations
The purpose of this study is to test different doses of abemaciclib to find the best dose in participants while receiving hormone therapy and radiati...
Phase 1
Commack, New York, United States and 6 other locations
therapy as a treatment after surgery for hormone receptor positive breast cancer.The study drugs involved in this study are:* A com...
Phase 2
Stamford, Connecticut, United States and 27 other locations
This is a randomized trial for patients with metastatic hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative breast...
Phase 2
Stony Brook, New York, United States and 12 other locations
Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies avail...
Phase 3
Port Jefferson Station, New York, United States and 35 other locations
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, Estrogen Rec ...
Phase 2
New Haven, Connecticut, United States and 14 other locations
Clinical trials
Research sites
Resources
Legal